Emergency Medicine Cases – Where the Experts Keep You in the Know. For show notes, quizzes, videos and more learning tools please visit emergencymedicinecases.com
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Chronic Lymphocytic Leukemia and Lymphoma | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Chronic Lymphocytic Leukemia and Bispecific Antibodies in the Management of Lymphoma
QUICKTIME•Episode home
Manage episode 423673863 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics:
- Introduction (0:00)
- First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44)
- The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08)
- Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17)
- The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45)
- The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43)
- The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48)
- Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19)
- Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25)
- Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44)
- Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19)
- The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17)
- Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59)
1395 episodes
QUICKTIME•Episode home
Manage episode 423673863 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics:
- Introduction (0:00)
- First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44)
- The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08)
- Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17)
- The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45)
- The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43)
- The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48)
- Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19)
- Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25)
- Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44)
- Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19)
- The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17)
- Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59)
1395 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.